Skip to content
Open access · CC-BY via OpenAlex

CDK12 Inactivation Attenuates Prostate Cancer Progression by Inhibiting BNIP3 ‐Mediated Mitophagy

Mengjun Huang, Hanqi Lei, Tongyu Tong, Hailin Zou, Binyuan Yan, Fei Cao, Yiting Wang, Qiliang Teng, Bin Xu, Juan Luo, Yupeng Guan, Shaohong Lai, Peng Li, Jun Pang

Cell Proliferation · 2025 · ▲ 3 citations

Abstract

Mitochondrial stress-induced mitophagy plays a critical role to maintain cellular homeostasis; however, in cancer cells, this process may also contribute to drug resistance. Our previous work identified CDK12 as a critical regulator of prostate cancer (PCa) cell survival under sustained enzalutamide exposure, though the precise mechanism remains to be elucidated. In this study, we hypothesize that CDK12 plays a key role in mitophagy regulation under mitochondrial stress, potentially modulating PCa cell resistance to enzalutamide, the first-line clinical medication in PCa therapy. Utilising multiple in vitro PCa cell models, we demonstrate that both CDK12 knockdown and pharmacological inhibition with THZ531 impaired mitophagy following treatment with enzalutamide and mitophagy inducer CCCP. Mechanistically, our finding reveal that CDK12 inhibition disrupts FOXO3-induced BNIP3 transcription, thereby preventing receptor-mediated mitophagy and sensitising PCa cells to enzalutamide. This study identifies the CDK12-FOXO3-BNIP3 pathway as a novel regulatory mechanism governing mitophagy under mitochondrial stress. Importantly, these results underscore CDK12's role in preserving mitochondrial function and promoting PCa cell survival during enzalutamide treatment. These findings highlight the therapeutic potential of targeting the CDK12-BNIP3-mitophagy axis in combination with antiandrogen therapies, offering a promising strategy to overcome drug resistance in PCa and improve clinical outcomes.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1111/cpr.70091
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Huang, M., Lei, H., Tong, T., Zou, H., Yan, B., Cao, F., Wang, Y., Teng, Q., Xu, B., Luo, J., Guan, Y., Lai, S., Li, P., &amp; Pang, J. (2025). CDK12 Inactivation Attenuates Prostate Cancer Progression by Inhibiting BNIP3 ‐Mediated Mitophagy. <em>Cell Proliferation</em>. https://doi.org/10.1111/cpr.70091
Vancouver
Huang M, Lei H, Tong T, Zou H, Yan B, Cao F, et al. CDK12 Inactivation Attenuates Prostate Cancer Progression by Inhibiting BNIP3 ‐Mediated Mitophagy. Cell Proliferation. 2025. doi:10.1111/cpr.70091.
BibTeX
@article{mengjun2025CDKIna, title = {CDK12 Inactivation Attenuates Prostate Cancer Progression by Inhibiting BNIP3 ‐Mediated Mitophagy}, author = {Mengjun Huang and Hanqi Lei and Tongyu Tong and Hailin Zou and Binyuan Yan and Fei Cao and Yiting Wang and Qiliang Teng and Bin Xu and Juan Luo and Yupeng Guan and Shaohong Lai and Peng Li and Jun Pang}, journal = {Cell Proliferation}, year = {2025}, doi = {10.1111/cpr.70091}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings